Interplay between parkin and p53 governs a physiological homeostasis that is disrupted in Parkinson's disease and cerebral cancer.
Identifieur interne : 000516 ( PubMed/Checkpoint ); précédent : 000515; suivant : 000517Interplay between parkin and p53 governs a physiological homeostasis that is disrupted in Parkinson's disease and cerebral cancer.
Auteurs : F. Checler [France] ; C. Alves Da CostaSource :
- Neuro-degenerative diseases [ 1660-2862 ] ; 2014.
English descriptors
- KwdEn :
- Animals, Brain Neoplasms (genetics), Brain Neoplasms (metabolism), Brain Neoplasms (pathology), Gene Expression Regulation, Homeostasis (physiology), Humans, Parkinson Disease (genetics), Parkinson Disease (metabolism), Parkinson Disease (pathology), Tumor Suppressor Protein p53 (genetics), Tumor Suppressor Protein p53 (metabolism), Ubiquitin-Protein Ligases (genetics), Ubiquitin-Protein Ligases (metabolism).
- MESH :
- chemical , genetics : Tumor Suppressor Protein p53, Ubiquitin-Protein Ligases.
- genetics : Brain Neoplasms, Parkinson Disease.
- metabolism : Brain Neoplasms, Parkinson Disease, Tumor Suppressor Protein p53, Ubiquitin-Protein Ligases.
- pathology : Brain Neoplasms, Parkinson Disease.
- physiology : Homeostasis.
- Animals, Gene Expression Regulation, Humans.
Abstract
Parkin is responsible for most autosomal juvenile recessive cases of Parkinson's disease (PD). Besides its well-characterized function as ubiquitin ligase, we previously established that parkin could repress p53 at the transcriptional level. Interestingly, p53 was recently shown to upregulate parkin, suggesting a feedback loop by which parkin and p53 interplay, thereby contributing to their physiological homeostasis. This equilibrium is disrupted in both PD and cerebral cancer. Thus, when parkin is mutated in PD, its transcriptional ability to repress p53 is abolished. Therefore, p53 elevation could likely contribute to the exacerbated cell death observed in PD-affected brains. Inversely, in brain-associated tumors linked to p53 mutations, the transcriptional control of parkin is reduced, and thereby, parkin expression is lowered. The reduction in parkin level could, in turn, contribute to an increase in the levels of transcriptionally inactive p53 that could explain, at least in part, the defect in cellular apoptotic commitment observed in cerebral cancer. Here, we discuss in detail the various studies demonstrating the importance of the functional interplay between parkin and p53 and its impairment by pathogenic mutations likely contributing to the etiology of PD and gliomas.
DOI: 10.1159/000354075
PubMed: 24008413
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:24008413Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interplay between parkin and p53 governs a physiological homeostasis that is disrupted in Parkinson's disease and cerebral cancer.</title><author><name sortKey="Checler, F" sort="Checler, F" uniqKey="Checler F" first="F" last="Checler">F. Checler</name><affiliation wicri:level="1"><nlm:affiliation>Institut de Pharmacologie Moléculaire et Cellulaire, Team Fondation pour la Recherche Médicale and Labex Distalz, Valbonne, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Pharmacologie Moléculaire et Cellulaire, Team Fondation pour la Recherche Médicale and Labex Distalz, Valbonne</wicri:regionArea><wicri:noRegion>Valbonne</wicri:noRegion><wicri:noRegion>Valbonne</wicri:noRegion></affiliation></author><author><name sortKey="Alves Da Costa, C" sort="Alves Da Costa, C" uniqKey="Alves Da Costa C" first="C" last="Alves Da Costa">C. Alves Da Costa</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24008413</idno><idno type="pmid">24008413</idno><idno type="doi">10.1159/000354075</idno><idno type="wicri:Area/PubMed/Corpus">000643</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000643</idno><idno type="wicri:Area/PubMed/Curation">000616</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000616</idno><idno type="wicri:Area/PubMed/Checkpoint">000616</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000616</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Interplay between parkin and p53 governs a physiological homeostasis that is disrupted in Parkinson's disease and cerebral cancer.</title><author><name sortKey="Checler, F" sort="Checler, F" uniqKey="Checler F" first="F" last="Checler">F. Checler</name><affiliation wicri:level="1"><nlm:affiliation>Institut de Pharmacologie Moléculaire et Cellulaire, Team Fondation pour la Recherche Médicale and Labex Distalz, Valbonne, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Pharmacologie Moléculaire et Cellulaire, Team Fondation pour la Recherche Médicale and Labex Distalz, Valbonne</wicri:regionArea><wicri:noRegion>Valbonne</wicri:noRegion><wicri:noRegion>Valbonne</wicri:noRegion></affiliation></author><author><name sortKey="Alves Da Costa, C" sort="Alves Da Costa, C" uniqKey="Alves Da Costa C" first="C" last="Alves Da Costa">C. Alves Da Costa</name></author></analytic><series><title level="j">Neuro-degenerative diseases</title><idno type="eISSN">1660-2862</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Brain Neoplasms (genetics)</term><term>Brain Neoplasms (metabolism)</term><term>Brain Neoplasms (pathology)</term><term>Gene Expression Regulation</term><term>Homeostasis (physiology)</term><term>Humans</term><term>Parkinson Disease (genetics)</term><term>Parkinson Disease (metabolism)</term><term>Parkinson Disease (pathology)</term><term>Tumor Suppressor Protein p53 (genetics)</term><term>Tumor Suppressor Protein p53 (metabolism)</term><term>Ubiquitin-Protein Ligases (genetics)</term><term>Ubiquitin-Protein Ligases (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Tumor Suppressor Protein p53</term><term>Ubiquitin-Protein Ligases</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Brain Neoplasms</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain Neoplasms</term><term>Parkinson Disease</term><term>Tumor Suppressor Protein p53</term><term>Ubiquitin-Protein Ligases</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain Neoplasms</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Homeostasis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Gene Expression Regulation</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkin is responsible for most autosomal juvenile recessive cases of Parkinson's disease (PD). Besides its well-characterized function as ubiquitin ligase, we previously established that parkin could repress p53 at the transcriptional level. Interestingly, p53 was recently shown to upregulate parkin, suggesting a feedback loop by which parkin and p53 interplay, thereby contributing to their physiological homeostasis. This equilibrium is disrupted in both PD and cerebral cancer. Thus, when parkin is mutated in PD, its transcriptional ability to repress p53 is abolished. Therefore, p53 elevation could likely contribute to the exacerbated cell death observed in PD-affected brains. Inversely, in brain-associated tumors linked to p53 mutations, the transcriptional control of parkin is reduced, and thereby, parkin expression is lowered. The reduction in parkin level could, in turn, contribute to an increase in the levels of transcriptionally inactive p53 that could explain, at least in part, the defect in cellular apoptotic commitment observed in cerebral cancer. Here, we discuss in detail the various studies demonstrating the importance of the functional interplay between parkin and p53 and its impairment by pathogenic mutations likely contributing to the etiology of PD and gliomas.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24008413</PMID><DateCreated><Year>2014</Year><Month>02</Month><Day>07</Day></DateCreated><DateCompleted><Year>2014</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1660-2862</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>2-3</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Neuro-degenerative diseases</Title><ISOAbbreviation>Neurodegener Dis</ISOAbbreviation></Journal><ArticleTitle>Interplay between parkin and p53 governs a physiological homeostasis that is disrupted in Parkinson's disease and cerebral cancer.</ArticleTitle><Pagination><MedlinePgn>118-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000354075</ELocationID><Abstract><AbstractText>Parkin is responsible for most autosomal juvenile recessive cases of Parkinson's disease (PD). Besides its well-characterized function as ubiquitin ligase, we previously established that parkin could repress p53 at the transcriptional level. Interestingly, p53 was recently shown to upregulate parkin, suggesting a feedback loop by which parkin and p53 interplay, thereby contributing to their physiological homeostasis. This equilibrium is disrupted in both PD and cerebral cancer. Thus, when parkin is mutated in PD, its transcriptional ability to repress p53 is abolished. Therefore, p53 elevation could likely contribute to the exacerbated cell death observed in PD-affected brains. Inversely, in brain-associated tumors linked to p53 mutations, the transcriptional control of parkin is reduced, and thereby, parkin expression is lowered. The reduction in parkin level could, in turn, contribute to an increase in the levels of transcriptionally inactive p53 that could explain, at least in part, the defect in cellular apoptotic commitment observed in cerebral cancer. Here, we discuss in detail the various studies demonstrating the importance of the functional interplay between parkin and p53 and its impairment by pathogenic mutations likely contributing to the etiology of PD and gliomas.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Checler</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Moléculaire et Cellulaire, Team Fondation pour la Recherche Médicale and Labex Distalz, Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alves da Costa</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neurodegener Dis</MedlineTA><NlmUniqueID>101189034</NlmUniqueID><ISSNLinking>1660-2854</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="C111567">parkin protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="Y">Homeostasis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>04</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>06</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24008413</ArticleId><ArticleId IdType="pii">000354075</ArticleId><ArticleId IdType="doi">10.1159/000354075</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country></list><tree><noCountry><name sortKey="Alves Da Costa, C" sort="Alves Da Costa, C" uniqKey="Alves Da Costa C" first="C" last="Alves Da Costa">C. Alves Da Costa</name></noCountry><country name="France"><noRegion><name sortKey="Checler, F" sort="Checler, F" uniqKey="Checler F" first="F" last="Checler">F. Checler</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000516 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000516 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:24008413
|texte= Interplay between parkin and p53 governs a physiological homeostasis that is disrupted in Parkinson's disease and cerebral cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:24008413" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |